Restenosis rates following vertebral artery origin stenting: Does stent type make a difference

Journal of Invasive Cardiology

Volumn 22, Issue 3, 2010, Pages 119-124

  Ogilvy, Christopher S ^a,b,d   Yang, Xinyu ^a,e   Natarajan, Sabareesh K ^b,d   Hauck, Erik F ^b,d   Sun, Luona ^b,c   Lewis Mason, Laura ^b,d   Hopkins, L Nelson ^b,c,d   Siddiqui, Adnan H ^b,c,d   Levy, Elad I ^b,c,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Toshiba Stroke Research Center   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d Millard Fillmore Gates Circle Hospital   (United States)

^e TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Endovascular treatment; Extracranial atherosclerotic disease; Restenosis; Sirolimus and paclitaxel eluting stents; Vertebral artery origin stenosis

Indexed keywords

PACLITAXEL; RAPAMYCIN;

ADULT; AGED; ARTICLE; CAROTID ARTERY OBSTRUCTION; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DISEASE SEVERITY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; MALE; RADIODIAGNOSIS; RESTENOSIS; RETREATMENT; REVASCULARIZATION; TRANSLUMINAL CORONARY ANGIOPLASTY; VERTEBRAL ARTERY STENOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; RECURRENCE; RETROSPECTIVE STUDIES; SIROLIMUS; STENTS; TREATMENT OUTCOME; VERTEBROBASILAR INSUFFICIENCY;

EID: 77749340144     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Albuquerque FC, Fiorella D, Han P, et al. A reappraisal of angioplasty and stenting for the treatment of vertebral origin stenosis. Neurosurgery 2003;53:607-616.
2. Caplan LR, Wityk RJ, Glass TA, et al. New England Medical Center Posterior Circulation registry. Ann Neurol 2004;56:389-398.
3. Cloud GC, Crawley F, Clifton A, et al. Vertebral artery origin angioplasty and primary stenting: Safety and restenosis rates in a prospective series. J Neurol Neurosurg Psychiatry 2003;74:586-590.
4. Malek AM, Higashida RT, Halbach VV, et al. Tandem intracranial stent deployment for treatment of an iatrogenic, flow-limiting, basilar artery dissection: Technical case report. Neurosurgery 1999;45:919-924.
5. Weber W, Mayer TE, Henkes H, et al. Efficacy of stent angioplasty for symptomatic stenoses of the proximal vertebral artery. Eur J Radiol 2005;56:240-247.
6. Moufarrij NA, Little JR, Furlan AJ, et al. Vertebral artery stenosis: Long-term follow-up. Stroke 1984;15:260-263.
7. Wehman JC, Hanel RA, Guidot CA, et al. Atherosclerotic occlusive extracranial vertebral artery disease: Indications for intervention, endovascular techniques, short-term and long-term results. J Interv Cardiol 2004;17:219-232.
8. Thevenet A, Ruotolo C. Surgical repair of vertebral artery stenoses. J Cardiovasc Surg (Torino) 1984;25:101-110.
9. Diaz FG, Ausman JI, de los Reyes RA, et al. Surgical reconstruction of the proximal vertebral artery. J Neurosurg 1984;61:874-881.
10. Hanel RA, Brasiliense LB, Spetzler RF. Microsurgical revascularization of proximal vertebral artery: A single-center, single-operator analysis. Neurosurgery 2009;64:1043-1051.
11. Dabus G, Gerstle RJ, Derdeyn CP, et al. Endovascular treatment of the vertebral artery origin in patients with symptoms of vertebrobasilar ischemia. Neuroradiology 2006;48:917-923.
12. Lin YH, Liu YC, Tseng WY, et al. The impact of lesion length on angiographic restenosis after vertebral artery origin stenting. Eur J Vasc Endovasc Surg 2006;32:379-385.
13. Mahadevia AA, Murphy KP. Endovascular treatment of vertebral artery origin lesions. Tech Vasc Interv Radiol 2005;8:131-133.
14. SSYLVIA Investigators. Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries (SSYLVIA): Study results. Stroke 2004;35:1388-1392.
15. Akins PT, Kerber CW, Pakbaz RS. Stenting of vertebral artery origin atherosclerosis in high-risk patients: Bare or coated? A single-center consecutive case series. J Invasive Cardiol 2008;20:14-20.
16. Edgell RC, Yavagal DR, Drazin D, et al. Treatment of vertebral artery origin stenosis with anti-proliferative drug-eluting stents (doi 10.1111/j.1552-6569.2008.00330.x). J Neuroimaging epub February 12, 2008.
17. Kim SR, Baik MW, Yoo SH, et al. Stent fracture and restenosis after placement of a drug-eluting device in the vertebral artery origin and treatment with the stent-in-stent technique. Report of two cases. J Neurosurg 2007;106:907-911.
18. Lin YH, Hung CS, Tseng WY, et al. Safety and feasibility of drug-eluting stent implantation at vertebral artery origin: The first case series in Asians. J Formos Med Assoc 2008;107:253-258.
19. Qureshi AI, Kirmani JF, Harris-Lane P, et al. Vertebral artery origin stent placement with distal protection: Technical and clinical results. AJNR Am J Neuroradiol 2006;27:1140-1145.
20. Zavala-Alarcon E, Emmans L, Little R, Bant A. Percutaneous intervention for posterior fossa ischemia. A single center experience and review of the literature. Int J Cardiol 2008;127:70-77.
21. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-Year outcomes and results from multiple imaging methods. Lancet 2009;373:897-910.
22. Stone GW, Midei M, Newman W, et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: Two-year clinical follow-up from the clinical evaluation of the Xience V everolimus-eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions (SPIRIT) III trial. Circulation 2009;119:680-686.
23. Stone GW, Midei M, Newman W, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: A randomized trial. JAMA 2008;299:1903-1913.
24. Parkinson RJ, Demers CP, Adel JG, et al. Use of heparin-coated stents in neurovascular interventional procedures: Preliminary experience with 10 patients. Neurosurgery 2006;59:812-821.
25. CAVATAS Investigators. Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): A randomised trial. Lancet 2001;357:1729-1737.
26. Gurm HS, Yadav JS, Fayad P, et al. Long-term results of carotid stenting versus endarterectomy in high-risk patients. N Engl J Med 2008;358:1572-1579.
27. Canyigit M, Arat A, Cil BE, et al. Management of vertebral stenosis complicated by presence of acute thrombus. Cardiovasc Intervent Radiol 2007;30:317-320.
28. Eberhardt O, Naegele T, Raygrotzki S, et al. Stenting of vertebrobasilar arteries in symptomatic atherosclerotic disease and acute occlusion: Case series and review of the literature. J Vasc Surg 2006;43:1145-1154.
29. Hayashi K, Kitagawa N, Morikawa M, Kaminogo M. A case of intimal hyperplasia induced by stenting for vertebral artery origin stenosis: assessed on intravascular ultrasound. Neurol Res 2003;25:357-360.
30. Kizilkilic O. Vertebral artery origin stenting with buddy wire technique in tortuous subclavian artery. Eur J Radiol 2007;61:120-123.
31. Piotin M, Spelle L, Martin JB, et al. Percutaneous transluminal angioplasty and stenting of the proximal vertebral artery for symptomatic stenosis. AJNR Am J Neuroradiol 2000;21:727-731.
32. Taylor RA, Siddiq F, Suri MF, et al. Risk factors for in-stent restenosis after vertebral ostium stenting. J Endovasc Ther 2008;15:203-212.
33. Mathias DW, Mooney JF, Lange HW, et al. Frequency of success and complications of coronary angioplasty of a stenosis at the ostium of a branch vessel. Am J Cardiol 1991;67:491-495.
34. Bosiers M, Cagiannos C, Deloose K, et al. Drug-eluting stents in the management of peripheral arterial disease. Vasc Health Risk Manag 2008;4:553-559.
35. Gaspardone A, Versaci F, Tomai F, et al. C-reactive protein, clinical outcome, and restenosis rates after implantation of different drug-eluting stents. Am J Cardiol 2006;97:1311-1316.
36. Pendyala L, Jabara R, Shinke T, et al. Drug-eluting stents: Present and future. Cardiovasc Hematol Agents Med Chem 2008;6:105-115.
37. Silva GV, Fernandes MR, Madonna R, et al. Comparative healing response after sirolimus- and paclitaxel-eluting stent implantation in a pig model of restenosis. Catheter Cardiovasc Interv 2009;73:801-808.
38. Na JO, Kim JW, Choi CU, et al. Bare-metal stents versus drug-eluting stents in large (>/=3.5 mm) single coronary artery: Angiographic and clinical outcomes at 6 months. J Cardiol 2009;54:108-114.
39. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
40. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
41. Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: A randomized controlled trial. JAMA 2005;294:1215-1223.
42. Quizhpe AR, Feres F, de Ribamar Costa J Jr, et al. Drug-eluting stents vs bare metal stents for the treatment of large coronary vessels. Am Heart J 2007;154:373-378.
43. Steinberg DH, Mishra S, Javaid A, et al. Comparison of effectiveness of bare metal stents versus drug-eluting stents in large (> or = 3.5 mm) coronary arteries. Am J Cardiol 2007;99:599-602.
44. Pache J, Dibra A, Mehilli J, et al. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: A prospective, randomized trial. Eur Heart J 2005;26:1262-1268.
45. Elezi S, Kastrati A, Neumann FJ, et al. Vessel size and long-term outcome after coronary stent placement. Circulation 1998;98:1875-1880.
46. Boulos AS, Agner C, Deshaies EM. Preliminary evidence supporting the safety of drug-eluting stents in neurovascular disease. Neurol Res 2005;27(Suppl 1):S95-102.
47. Gupta R, Al-Ali F, Thomas AJ, et al. Safety, feasibility, and short-term follow-up of drug-eluting stent placement in the intracranial and extracranial circulation. Stroke 2006;37:2562-2566.